Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy

Mauro Viganò, Giampaolo Mangia, Pietro Lampertico

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Introduction: Rituximab (RTX), a chimeric mouse anti-human CD20 monoclonal antibody, is indicated for the treatment of patients with non-Hodgkin's lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis and microscopic polyangiitis, and rheumatoid arthritis, but nowadays it is increasingly used for the treatment of many other immune-mediated disorders. Hepatitis B virus (HBV) reactivation in RTX-treated patients, eventually leading to fatal liver failure, has been reported more often among hepatitis B surface antigen (HBsAg)-positive patients (overt infection) than in HBsAg-negative, antibody to hepatitis B core antigen (anti-HBc) seropositive patients (resolved infection). Areas covered: This paper reviews the safety of RTX in patients with overt or resolved HBV infection, providing recommendations for its safe use in such patients. Expert opinion: Prior to starting RTX treatment, all patients should be screened for HBV infection. While HBsAg-positive active carriers should receive long-term antiviral treatment with entecavir (ETV) or tenofovir, inactive carriers are candidates for universal prophylaxis with lamivudine, or ETV or tenofovir in selected cases, to prevent hepatitis reactivation. Conversely, for HBsAg-negative anti-HBc positive carriers, that is, those with resolved HBV infection, universal prophylaxis with lamivudine is recommended for those with onco-hematological diseases, whereas watchful monitoring of HBsAg/HBV DNA levels is advisable for all the other indications.

Original languageEnglish
Pages (from-to)1019-1031
Number of pages13
JournalExpert Opinion on Biological Therapy
Volume14
Issue number7
DOIs
Publication statusPublished - 2014

Fingerprint

Virus Diseases
Hepatitis B Surface Antigens
Viruses
Hepatitis B virus
Tenofovir
Hepatitis B Core Antigens
Lamivudine
Therapeutics
Antibodies
Microscopic Polyangiitis
Liver
Antiviral Agents
Granulomatosis with Polyangiitis
Hematologic Diseases
Immune System Diseases
Liver Failure
Expert Testimony
B-Cell Chronic Lymphocytic Leukemia
Monoclonal Antibodies
Infection

Keywords

  • Chemotherapy
  • Hepatitis B reactivation
  • Hepatitis B virus
  • Nucleos(t)ides analogs
  • Prophylaxis
  • Rituximab

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Biochemistry
  • Drug Discovery
  • Medicine(all)

Cite this

Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy. / Viganò, Mauro; Mangia, Giampaolo; Lampertico, Pietro.

In: Expert Opinion on Biological Therapy, Vol. 14, No. 7, 2014, p. 1019-1031.

Research output: Contribution to journalArticle

@article{3fa83ee34a3c442e9f0ffdc32312cc03,
title = "Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy",
abstract = "Introduction: Rituximab (RTX), a chimeric mouse anti-human CD20 monoclonal antibody, is indicated for the treatment of patients with non-Hodgkin's lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis and microscopic polyangiitis, and rheumatoid arthritis, but nowadays it is increasingly used for the treatment of many other immune-mediated disorders. Hepatitis B virus (HBV) reactivation in RTX-treated patients, eventually leading to fatal liver failure, has been reported more often among hepatitis B surface antigen (HBsAg)-positive patients (overt infection) than in HBsAg-negative, antibody to hepatitis B core antigen (anti-HBc) seropositive patients (resolved infection). Areas covered: This paper reviews the safety of RTX in patients with overt or resolved HBV infection, providing recommendations for its safe use in such patients. Expert opinion: Prior to starting RTX treatment, all patients should be screened for HBV infection. While HBsAg-positive active carriers should receive long-term antiviral treatment with entecavir (ETV) or tenofovir, inactive carriers are candidates for universal prophylaxis with lamivudine, or ETV or tenofovir in selected cases, to prevent hepatitis reactivation. Conversely, for HBsAg-negative anti-HBc positive carriers, that is, those with resolved HBV infection, universal prophylaxis with lamivudine is recommended for those with onco-hematological diseases, whereas watchful monitoring of HBsAg/HBV DNA levels is advisable for all the other indications.",
keywords = "Chemotherapy, Hepatitis B reactivation, Hepatitis B virus, Nucleos(t)ides analogs, Prophylaxis, Rituximab",
author = "Mauro Vigan{\`o} and Giampaolo Mangia and Pietro Lampertico",
year = "2014",
doi = "10.1517/14712598.2014.912273",
language = "English",
volume = "14",
pages = "1019--1031",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Taylor and Francis Ltd.",
number = "7",

}

TY - JOUR

T1 - Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy

AU - Viganò, Mauro

AU - Mangia, Giampaolo

AU - Lampertico, Pietro

PY - 2014

Y1 - 2014

N2 - Introduction: Rituximab (RTX), a chimeric mouse anti-human CD20 monoclonal antibody, is indicated for the treatment of patients with non-Hodgkin's lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis and microscopic polyangiitis, and rheumatoid arthritis, but nowadays it is increasingly used for the treatment of many other immune-mediated disorders. Hepatitis B virus (HBV) reactivation in RTX-treated patients, eventually leading to fatal liver failure, has been reported more often among hepatitis B surface antigen (HBsAg)-positive patients (overt infection) than in HBsAg-negative, antibody to hepatitis B core antigen (anti-HBc) seropositive patients (resolved infection). Areas covered: This paper reviews the safety of RTX in patients with overt or resolved HBV infection, providing recommendations for its safe use in such patients. Expert opinion: Prior to starting RTX treatment, all patients should be screened for HBV infection. While HBsAg-positive active carriers should receive long-term antiviral treatment with entecavir (ETV) or tenofovir, inactive carriers are candidates for universal prophylaxis with lamivudine, or ETV or tenofovir in selected cases, to prevent hepatitis reactivation. Conversely, for HBsAg-negative anti-HBc positive carriers, that is, those with resolved HBV infection, universal prophylaxis with lamivudine is recommended for those with onco-hematological diseases, whereas watchful monitoring of HBsAg/HBV DNA levels is advisable for all the other indications.

AB - Introduction: Rituximab (RTX), a chimeric mouse anti-human CD20 monoclonal antibody, is indicated for the treatment of patients with non-Hodgkin's lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis and microscopic polyangiitis, and rheumatoid arthritis, but nowadays it is increasingly used for the treatment of many other immune-mediated disorders. Hepatitis B virus (HBV) reactivation in RTX-treated patients, eventually leading to fatal liver failure, has been reported more often among hepatitis B surface antigen (HBsAg)-positive patients (overt infection) than in HBsAg-negative, antibody to hepatitis B core antigen (anti-HBc) seropositive patients (resolved infection). Areas covered: This paper reviews the safety of RTX in patients with overt or resolved HBV infection, providing recommendations for its safe use in such patients. Expert opinion: Prior to starting RTX treatment, all patients should be screened for HBV infection. While HBsAg-positive active carriers should receive long-term antiviral treatment with entecavir (ETV) or tenofovir, inactive carriers are candidates for universal prophylaxis with lamivudine, or ETV or tenofovir in selected cases, to prevent hepatitis reactivation. Conversely, for HBsAg-negative anti-HBc positive carriers, that is, those with resolved HBV infection, universal prophylaxis with lamivudine is recommended for those with onco-hematological diseases, whereas watchful monitoring of HBsAg/HBV DNA levels is advisable for all the other indications.

KW - Chemotherapy

KW - Hepatitis B reactivation

KW - Hepatitis B virus

KW - Nucleos(t)ides analogs

KW - Prophylaxis

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=84902138609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902138609&partnerID=8YFLogxK

U2 - 10.1517/14712598.2014.912273

DO - 10.1517/14712598.2014.912273

M3 - Article

C2 - 24909454

AN - SCOPUS:84902138609

VL - 14

SP - 1019

EP - 1031

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 7

ER -